Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant by Ishani Landry, Jagadeesh Aluri, Nancy Hall, Dinesh Kumar, Satish Dayal, Margaret Moline, Larisa Reyderman

Connect to this object online.

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant by Satish Dayal, Jagadeesh Aluri, Nancy Hall, Gleb Filippov, Margaret Moline, Larisa Reyderman, Ishani Landry

Connect to this object online.

Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial by Yoshikazu Takaesu, Masahiro Suzuki, Margaret Moline, Kate Pinner, Kanako Inabe, Yurie Nishi, Kenichi Kuriyama

Connect to this object online.

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant by Ishani Landry, Jagadeesh Aluri, Nancy Hall, Gleb Filippov, Satish Dayal, Margaret Moline, Larisa Reyderman

Connect to this object online.

Re-examining the factor structure of the Insomnia Severity Index (ISI) and defining the meaningful within-individual change (MWIC) for subjects with insomnia disorder in two phase... by William R. Lenderking, Yulia Savva, Mark J. Atkinson, Renee Campbell, Isabelle Chabot, Margaret Moline, Genevieve Meier, Charles M. Morin

Connect to this object online.

Evidence‐based insomnia treatment strategy using novel orexin antagonists: A review by Taro Kishi, Maika Nishida, Michinori Koebis, Takehiro Taninaga, Kenzo Muramoto, Naoki Kubota, Margaret Moline, Kenji Sakuma, Makoto Okuya, Ikuo Nomura, Nakao Iwata

Connect to this object online.